Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 6/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12939732 | 1.00 | MEN1 (0.57) | MEN1NPC1RAB9AKMT2AMME | |
| SCHEMBL21129085 | 1.00 | MEN1 (0.57) | MEN1NPC1RAB9AKMT2AMME | |
| SCHEMBL11237591 | 0.89 | TBXAS1 (0.59) | MMETBXAS1PTGS1PTGS2LMNA | |
| SCHEMBL22235331 | 0.84 | KMT2A (0.53) | MEN1NPC1RAB9AKMT2AMME | |
| SCHEMBL19553694 | 0.83 | PTGS1 (0.66) | TBXAS1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL13643239 | 0.82 | EPHX1 (0.57) | MEN1NPC1RAB9AKMT2AMME | |
| SCHEMBL30563831 | 0.82 | KMT2A (0.51) | MEN1NPC1RAB9AKMT2AMME | |
| SCHEMBL2720266 | 0.82 | EPHX1 (0.57) | MEN1NPC1RAB9AKMT2AMME | |
| SCHEMBL13968367 | 0.82 | MEN1 (0.51) | MEN1NPC1RAB9AKMT2AMME | |
| SCHEMBL11996333 | 0.82 | TBXAS1 (0.53) | MEN1KMT2ATBXAS1ACACBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024002270-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2024-01-04 | — | — | WO | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| EP-4222151-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023143603-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022222888-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2022-10-27 | — | — | WO | disclosed |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| EP-3730502-A1 | SYNTHESIS AND APPLICATION OF OXASPIROCYCLODIPHOSPHINE LIGAND | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2020-10-28 | — | — | EP | disclosed |
| WO-2019153203-A1 | SYNTHESIS AND APPLICATION OF OXASPIROCYCLODIPHOSPHINE LIGAND | 凯特立斯（深圳）科技有限公司 | 2019-08-15 | — | — | WO | disclosed |
| WO-2018149419-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2018-08-23 | — | — | WO | disclosed |
| EP-0832082-B1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| US-6271248-B1 | USED IN TREATING HYPERTENSION, PULMONARY HYPERTENSION, RENAL/ GLOMERULAR/MESANGIAL CELL DISORDERS, ENDOTOXEMIA, ISCHEMIA, TUMOR GROWTH, ATHERSCLEROSIS, RESTENOSIS, SUBARACHNOID HEMORRHAGE, PROSTATIC HYPERTROPHY, CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6258817-B1 | PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | ZENECA LTD. (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6080774-A | Substituted biphenylsulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-27 | — | — | US | disclosed |
| US-6060475-A | Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof | ZENECA LIMITED (GB) | 2000-05-09 | — | — | US | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| CN-1192739-A | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists | ZENECA LTD (GB) | 1998-09-09 | — | — | CN | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| EP-0768305-A1 | N-Isoxazolyl-biphenylsulfonamide derivatives, their preparation and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | MEN1 2371/4885NPC1 2323/4885RAB9A 2235/4885 |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | MEN1 1797/4885NPC1 600/4885RAB9A 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.